3.205

3.20% -0.075

Macrogenics Inc (MGNX)

Overview News Price History Option Chain Financials Discussions Forecast

Macrogenics Inc stock is traded at $3.205, with a volume of 69,854. It is down -3.20% in the last 24 hours and down -17.75% over the past month. Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).

Previous Close:

$3.28

Open:

$3.25

24h Volume:

69,854

Relative Volume:

0.11

Market Cap:

$202.73M

Revenue:

$56.91M

Net Income/Loss:

$-9.06M

P/E Ratio:

26.71

EPS:

0.12

Net Cash Flow:

$-79.97M

1W Performance:

-16.67%

1M Performance:

-17.75%

6M Performance:

-25.47%

1Y Performance:

-57.15%

1-Day Range:

$3.16

$3.328

1-Week Range:

$3.16

$3.84

52-Week Range:

$2.9511

$21.88

Macrogenics Inc Stock (MGNX) Company Profile

Name

Macrogenics Inc

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

301-251-5172

Address

9704 MEDICAL CENTER DRIVE, Rockville, MD

Employee

339

Twitter

@macrogenics

Next Earnings Date

2024-11-05

Latest SEC Filings

MGNX's Discussions on Twitter

Compare MGNX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MGNX	3.205	202.73M	56.91M	-9.06M	-79.97M	0.12
VRTX	447.00	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	739.78	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	590.30	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	249.57	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	103.41	24.49B	3.30B	-501.07M	1.03B	11.54

Macrogenics Inc Stock (MGNX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-20-23	Upgrade	Citigroup	Neutral → Buy
Nov-07-23	Upgrade	Guggenheim	Neutral → Buy
Mar-17-23	Downgrade	Guggenheim	Buy → Neutral
Nov-22-22	Downgrade	Cowen	Outperform → Market Perform
Nov-14-22	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jul-18-22	Downgrade	SMBC Nikko	Outperform → Neutral
Jul-11-22	Downgrade	BMO Capital Markets	Outperform → Market Perform
May-04-22	Downgrade	Guggenheim	Buy → Neutral
Feb-28-22	Upgrade	Citigroup	Neutral → Buy
Feb-11-22	Initiated	BMO Capital Markets	Outperform
Feb-04-22	Initiated	SMBC Nikko	Outperform
Nov-17-21	Resumed	Guggenheim	Buy
Oct-19-21	Initiated	JMP Securities	Mkt Outperform
Oct-15-21	Resumed	BTIG Research	Buy
Apr-26-21	Resumed	Credit Suisse	Outperform
Mar-12-21	Upgrade	Barclays	Underweight → Overweight
Dec-22-20	Resumed	H.C. Wainwright	Buy
Aug-03-20	Downgrade	Citigroup	Buy → Neutral
Jun-01-20	Upgrade	Guggenheim	Neutral → Buy
May-26-20	Reiterated	H.C. Wainwright	Buy
Mar-04-20	Initiated	Barclays	Underweight
Dec-19-19	Initiated	Cantor Fitzgerald	Overweight
Dec-18-19	Initiated	Cantor Fitzgerald	Overweight
Nov-21-19	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Nov-20-19	Resumed	Guggenheim	Neutral
May-03-19	Upgrade	Wedbush	Neutral → Outperform
Apr-12-19	Initiated	Guggenheim	Neutral
Feb-07-19	Upgrade	Citigroup	Sell → Buy
Feb-07-19	Downgrade	Wedbush	Outperform → Neutral
Feb-06-19	Upgrade	Raymond James	Underperform → Mkt Perform
Feb-04-19	Downgrade	Citigroup	Neutral → Sell
Dec-10-18	Downgrade	Raymond James	Outperform → Underperform
Sep-10-18	Resumed	BTIG Research	Buy
May-31-18	Initiated	Evercore ISI	Outperform
Mar-05-18	Initiated	H.C. Wainwright	Buy
Mar-31-17	Initiated	Raymond James	Outperform

View All

Macrogenics Inc Stock (MGNX) Latest News

Nov 20, 2024

MacroGenics, Inc. (NASDAQ:MGNX) Receives Average Rating of "Hold" from Analysts - MarketBeat

Nov 20, 2024

Nov 14, 2024

MacroGenics' SWOT analysis: biotech stock faces pipeline hurdles amid cash strength - Investing.com India

Nov 14, 2024

Nov 11, 2024

MacroGenics downgraded to Market Perform from Outperform at JMP Securities - TipRanks

Nov 07, 2024

Peeling Back The Layers: Exploring Macrogenics Through Analyst Insights - Benzinga

Nov 07, 2024

MacroGenics, Inc. (NASDAQ:MGNX) Q2 2024 Earnings Call Transcript - Insider Monkey

Nov 07, 2024

MacroGenics (NASDAQ:MGNX) Rating Lowered to "Market Perform" at JMP Securities - MarketBeat

Nov 07, 2024

MacroGenics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St

Nov 07, 2024

Nov 06, 2024

MacroGenics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 06, 2024

MacroGenics to Participate in Upcoming Investor Conferences - GlobeNewswire

Nov 06, 2024

MacroGenics (MGNX) to Present at Guggenheim and Stifel Healthcare Conferences | MGNX Stock News - StockTitan

Nov 06, 2024

Earnings call: MacroGenics reports a revenue jump to $110.7 million By Investing.com - Investing.com South Africa

Nov 06, 2024

Earnings call: MacroGenics reports a revenue jump to $110.7 million - Investing.com India

Nov 06, 2024

MacroGenics Margenza rights sale a positive, says Leerink - TipRanks

Nov 06, 2024

MacroGenics (NASDAQ:MGNX) Receives Neutral Rating from HC Wainwright - MarketBeat

Nov 06, 2024

MacroGenics Inc earnings beat by $0.69, revenue topped estimates - Investing.com Australia

Nov 06, 2024